Ivonescimab Demonstrates Promising Survival Results in First-Line Treatment for NSCLC
Recent findings from the HARMONi-2 trial reveal that Ivonescimab significantly improves overall survival rates in patients with PD-L1-positive non-small cell lung cancer. The results were presented at the World Conference on Lung Cancer 2026, highlighting a potential new standard of care in oncology.